ArticleFrontiers in medicine2026
Efficacy and safety of Shufeng Huashi formula for post-infectious cough: study protocol for a randomized control trial.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-infectious cough (PIC) refers to a type of persistent cough triggered by respiratory tract infections that remains unresolved after the initial infection is controlled. It significantly impacts daily life, work, and overall quality of life. This study aims to evaluate the clinical efficacy and safety of the Shufeng Huashi (SFHS) formula, a Traditional Chinese Medicine (TCM) compound, in patients with PIC. Methods and analysis: This multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial will recruit 120 patients aged 18-65 who meet the diagnostic criteria for PIC. Participants will be randomly assigned to the SFHS group or the placebo group in a 2:1 ratio using a random coding table. The SFHS group will receive oral TCM treatment for 14 days, while the placebo group will receive a placebo for the same duration, both administered three times daily. The primary outcome measure is the cough relief rate on day 14. Secondary outcome measures include cough symptom scores (CSS), cough evaluation test (CET), TCM syndrome efficacy, Leicester Cough Questionnaire (LCQ) scores, cough cure rate, cough relief rate on day 7, time to cough cure, time to cough relief, and cough recurrence rate. Adverse events will be monitored and recorded throughout the study. Discussion: PIC is highly prevalent, yet current pharmacological treatment options remain limited. This trial is expected to generate evidence regarding the efficacy and safety of TCM in treating PIC and inform evidence-based recommendations for clinical practice. Clinical trial registration: https://itmctr.ccebtcm.org.cn/mgt/project/view/2038531670868623360, Identifier ITMCTR2025001210.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.